REDWOOD CITY, Calif., March 01, 2016 (GLOBE NEWSWIRE) -- Avinger, Inc. (NASDAQ:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today reported results for the fourth quarter and full year ended December 31, 2015.
Recent Highlights
* Commenced commercialization of an enhanced version of the Pantheris™ image-guided atherectomy system following receipt of a 510(k) clearance from the United States Food and Drug Administration (FDA) on March 1, 2016.
* Added 13 new lumivascular accounts during the fourth quarter of 2015, expanding the installed base of lumivascular platform customers to 95 accounts at year-end.
Recent Highlights
* Commenced commercialization of an enhanced version of the Pantheris™ image-guided atherectomy system following receipt of a 510(k) clearance from the United States Food and Drug Administration (FDA) on March 1, 2016.
* Added 13 new lumivascular accounts during the fourth quarter of 2015, expanding the installed base of lumivascular platform customers to 95 accounts at year-end.
